Fangyi Xiao

Dr. Fangyi Xiao

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2022 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
YCyihe chen
yihe chen
LWLiang‐Guo Wang
Liang‐Guo Wang
XZXiao-Dong Zhou
Xiao-Dong Zhou
YFYing Fang
Ying Fang
LSLan Su
Lan Su
FXFangyi Xiao
Fangyi Xiao

30 August 2013 in Chinese Medical Journal
Verified
Journal Article
Open access
DXDing-Cheng Xiang
Ding-Cheng Xiang
XGXiao-Long Gu
Xiao-Long Gu
YSYao-Ming Song
Yao-Ming Song
Weijian HuangWeijian Huang
Weijian Huang
LTLiangqiu Tang
Liangqiu Tang
ZLZengzhang Liu
Zengzhang Liu
Background: Bivalirudin was widely used as an anticoagulant during coronary interventional procedure in western countries. However, it was not available in China before this clinical trial was designed. This randomized, single-blind and multicenter clinical trial aimed to evaluate the efficacy and the safety of domestic bivalirudin during percutaneous coronary intervention (PCI). Methods: A randomized, single-blind, multicenter trial was designed. Elective PCI candidates in five centers were randomized into a bivalirudin group and a heparin group, which were treated with domestic bivalirudin and non-fractional heparin during the PCI procedure. The efficacy was evaluated by comparing the activated coagulation time (ACT), the procedural success rate (residual stenosis 0.05). Survival rates without major adverse cardiac events at 30 days after PCI were 100.0% in the bivalirudin group and 98.2% in the heparin group (P>0.05). Mild bleeding rates were 0.9% and 6.9% (P<0.05) at 24 hours, and 1.9% and 8.8% (P<0.05) at 30 days after PCI in the bivalirudin group and heparin group respectively. There was one severe gastrointestinal bleeding case in the heparin group. Conclusions: Domestic bivalirudin is an effective and safe anticoagulant during elective PCI procedures. The efficacy is not inferior to heparin, but the safety is superior to heparin.

30 March 2021 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
FXFangyi Xiao
Fangyi Xiao
YCYanyan Chen
Yanyan Chen
YCyihe chen
yihe chen
XZXiao-Dong Zhou
Xiao-Dong Zhou
XWXinlei Wu
Xinlei Wu
WHWeijian Huang
Weijian Huang

20 October 2021 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
ZMZhi-Jie Mao
Zhi-Jie Mao
YPYan Pei
Yan Pei
HLHui Lin
Hui Lin
YXYin Xiang
Yin Xiang
ZHZhouqing Huang
Zhouqing Huang
YCYi-He Chen
Yi-He Chen
Background: High-power radiofrequency (RF) catheter ablation was considered as a promising alternative strategy to conventional-power ablation in the treatment of patients with atrial fibrillation (AF). This study sought to compare the efficacy and safety of high-power energy delivery to that of conventional-power setting in AF catheter ablation.Methods: We performed a systematic review of relevant literature in Pubmed, Embase, Cochrane library, and Google Scholar database. Sixteen eligible studies totaling 3,307 patients (1,929 for high-power ablation; 1,378 for conventional-power ablation) met inclusion criteria.Results: During a median 12 month follow-up, high-power ablation showed a significantly higher AF/atrial tachycardia-free survival rate in comparison with conventional-power ablation (risk ratio [RR] 1.09, 95% CI 1.02 to 1.15, p = 0.008). Notably, a high-power strategy convincingly decreased the procedure time (weighted mean difference [WMD] −46.11 min, 95% CI −59.15 to −33.07, p < 0.001) and RF ablation time (WMD −19.19 min, 95% CI −24.47 to −13.90, p < 0.001), along with reduced fluoroscopy time (WMD −7.82 min, 95% CI −15.13 to −0.68, p = 0.036). In addition, there was no perceptible difference in the potential risk of procedure-related complications between these two approaches (RR 0.81, 95% CI 0.48 to 1.37, p = 0.428).Conclusions: High-power RF catheter ablation was associated with an improvement in long-term sinus rhythm maintenance for treatment of AF, without exacerbating the risk of adverse events during the procedure. Impressively, high-power pulmonary vein isolation had the potential to shorten the application duration and minimize fluoroscopic exposure.


28 February 2020 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
FXFangyi Xiao
Fangyi Xiao
WJWei Zhu Ju
Wei Zhu Ju
HCHong Wu Chen
Hong Wu Chen
WHWeijian Huang
Weijian Huang
MCminglong Chen
minglong Chen